AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,242,846 | -7.8% | 50,216 | +5.5% | 0.00% | 0.0% |
| Q2 2023 | $1,348,145 | +24.8% | 47,604 | +1.3% | 0.00% | 0.0% |
| Q1 2023 | $1,079,912 | -29.3% | 47,014 | -14.8% | 0.00% | 0.0% |
| Q4 2022 | $1,526,875 | -2.8% | 55,153 | -0.1% | 0.00% | 0.0% |
| Q3 2022 | $1,570,531 | +26.7% | 55,196 | -0.7% | 0.00% | 0.0% |
| Q2 2022 | $1,239,285 | -22.8% | 55,586 | +1.3% | 0.00% | 0.0% |
| Q1 2022 | $1,605,053 | +71.5% | 54,863 | +94.8% | 0.00% | 0.0% |
| Q4 2021 | $936,000 | -33.9% | 28,161 | -8.2% | 0.00% | 0.0% |
| Q3 2021 | $1,416,000 | -26.2% | 30,686 | -11.9% | 0.00% | -50.0% |
| Q2 2021 | $1,919,000 | +1261.0% | 34,830 | +1972.0% | 0.00% | – |
| Q2 2018 | $141,000 | +3.7% | 1,681 | +0.8% | 0.00% | – |
| Q1 2018 | $136,000 | +60.0% | 1,668 | +12.5% | 0.00% | – |
| Q4 2017 | $85,000 | -13.3% | 1,483 | +1.2% | 0.00% | – |
| Q3 2017 | $98,000 | +66.1% | 1,465 | +28.4% | 0.00% | – |
| Q2 2017 | $59,000 | -6.3% | 1,141 | +6.5% | 0.00% | – |
| Q1 2017 | $63,000 | +40.0% | 1,071 | 0.0% | 0.00% | – |
| Q4 2016 | $45,000 | -19.6% | 1,071 | +1.6% | 0.00% | – |
| Q3 2016 | $56,000 | +27.3% | 1,054 | -0.6% | 0.00% | – |
| Q2 2016 | $44,000 | +10.0% | 1,060 | +0.6% | 0.00% | – |
| Q1 2016 | $40,000 | -41.2% | 1,054 | 0.0% | 0.00% | – |
| Q4 2015 | $68,000 | -8.1% | 1,054 | 0.0% | 0.00% | – |
| Q3 2015 | $74,000 | -37.3% | 1,054 | -0.9% | 0.00% | – |
| Q2 2015 | $118,000 | -87.5% | 1,064 | -89.4% | 0.00% | -100.0% |
| Q1 2015 | $945,000 | -9.7% | 10,021 | +7.2% | 0.00% | -50.0% |
| Q4 2014 | $1,047,000 | +82.7% | 9,350 | +0.1% | 0.00% | +100.0% |
| Q3 2014 | $573,000 | +35.8% | 9,345 | +1.6% | 0.00% | 0.0% |
| Q2 2014 | $422,000 | +79.6% | 9,195 | +53.0% | 0.00% | – |
| Q1 2014 | $235,000 | +80.8% | 6,011 | +10.3% | 0.00% | – |
| Q4 2013 | $130,000 | +2500.0% | 5,449 | +2861.4% | 0.00% | – |
| Q3 2013 | $5,000 | – | 184 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |